

# KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

## Next Generation HIV Vaccines & Therapies (B4)

February 21-25, 2021 • Eldorado Hotel & Spa • Santa Fe, NM, USA

Scientific Organizers: Michel C. Nussenzweig, Robert F. Siliciano, John R. Mascola and Margaret E. Ackerman

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Discounted Abstract & Scholarship Deadline: November 4, 2020 / Abstract Deadline: November 19, 2020 / Discounted Registration Deadline: December 16, 2020

### SUNDAY, FEBRUARY 21

#### Arrival and Registration

### MONDAY, FEBRUARY 22

#### Welcome and Keynote Address

**Pamela J. Bjorkman**, California Institute of Technology, USA  
*A Molecular Arms Race: The Immune System versus HIV*

#### Human Immunization

**William Schief**, International AIDS Vaccine Initiative and The Scripps Research Institute, USA  
*Clinical Tests of Germline Targeting*

**Julie Ledgerwood**, NIAID, National Institutes of Health, USA  
*VRC01 Clinical Trials*

**M. Juliana McElrath**, Fred Hutchinson Cancer Research Center, USA  
*Env based Immunogenicity in the Clinic*

#### Short Talks Chosen from Abstracts

#### Passive Therapies

**Glenda Gray**, South African Medical Research Council, South Africa  
*The AMP Study*

**Marina F. Caskey**, Rockefeller University, USA  
*Human Studies with Combination bNAbs*

**Katharine Bar**, University of Pennsylvania, USA  
*Treatment Interruption after bNAb Administration*

#### Short Talks Chosen from Abstracts

#### Poster Session 1

### TUESDAY, FEBRUARY 23

#### Vaccine Immunology

##### Speaker to be Announced

##### Speaker to be Announced

**Gabriel D. Vitoria**, Rockefeller University, USA  
*Germinal Center Dynamics*

**Facundo D. Batista**, Ragon Institute of MGH, MIT and Harvard, USA  
*Mouse Models for HIV-1 Vaccines*

#### Short Talks Chosen from Abstracts

#### Immunization Strategies

**Neil P. King†**, University of Washington, USA  
*Synthetic Immunogenicity and Nanoparticles*

**Shane Crotty**, La Jolla Institute for Immunology, USA  
*Increasing the Breadth and Potency of Candidate HIV Vaccine Immune Responses*

**Darrell J. Irvine**, Massachusetts Institute of Technology, USA  
*Adjuvants in HIV-1 Vaccination*

#### Short Talks Chosen from Abstracts

#### Poster Session 2

### WEDNESDAY, FEBRUARY 24

#### HIV Immunology

**Penny L. Moore**, University of the Witwatersrand and National Institute for Communicable Diseases, South Africa  
*Viral vs. Antibody Diversification during Infection*

**Alexandra Trkola**, University of Zürich, Switzerland  
*Role of the Virus in Dictating the Immune Response*

**Beatrice H. Hahn**, University of Pennsylvania, USA  
*Exploiting the Ape Precursors of HIV-1 for AIDS Vaccine Design*

**Catherine A. Blish**, Stanford University School of Medicine, USA  
*Targeting Natural Killer Cells to HIV*

#### Short Talks Chosen from Abstracts

#### Control of Latency

**Robert F. Siliciano**, Johns Hopkins University School of Medicine, USA  
*The Nature of the Latent Reservoir*

*The Nature of the Latent Reservoir*

**Mary Carrington**, NCI, National Institutes of Health, USA  
*Immunogenetic Variation in Outcome to HIV Therapy*

**Bruce D. Walker**, Ragon Institute of MGH, MIT and Harvard, USA  
*How Elite Controllers Control*

#### Short Talks Chosen from Abstracts

#### Poster Session 3

### THURSDAY, FEBRUARY 25

#### Cure Related Human Trials

**Malcolm A. Martin**, National Institutes of Health, USA  
*Antibody Studies in SHIV Infected Macaques*

**Romas Geleziunas**, Gilead Sciences, Inc., USA  
*Developing Combination Therapies for Cure*

**Sharon R. Lewin**, University of Melbourne, Australia  
*The Latent Reservoir*

**Sarah Fidler**, Imperial College Faculty of Medicine, UK  
*Clinical Interventions and their Effects on Viral Rebound*

#### Short Talks Chosen from Abstracts

#### Session Title to be Determined

**Peter D. Kwong**, NIAID, National Institutes of Health, USA  
*HIV-1 Vaccination Targeting Specific Sites of Vulnerability*

**Rogier W. Sanders**, University of Amsterdam and Weill Cornell Medical College, Netherlands  
*SOSIP based Immunogens as Vaccines*

**Christopher O. Barnes**, California Institute of Technology, USA  
*Structures of HIV-1 Env Trimers Define Antibody-Mediated Neutralization of HIV-1*

#### Short Talks Chosen from Abstracts

#### Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

### FRIDAY, FEBRUARY 26

#### Departure